It did react to RP’s firing, if there was anything major concerning in the lawsuit, I believe we would have seen a reaction.
Funding definitely will get a big reaction. I’m been in other otc stocks and have made similar claims myself, nothing but revenue or funding, to see some insignificant event , at least to me, spark the share price taking off. With otc, you never know sometimes. It is almost never funding or revenue, because the nature of otc, few make funding agreements. Here though we have a great shot, soon I believe with funding. Then revenue comes with drug approval, so we are close.
Also, I believe the BLA submission will move the share price. We will see how much. And Mono pivotal approval. Then the partnership/licensing would be huge of course.
Funding definitely will get a big reaction. I’m been in other otc stocks and have made similar claims myself, nothing but revenue or funding, to see some insignificant event , at least to me, spark the share price taking off. With otc, you never know sometimes. It is almost never funding or revenue, because the nature of otc, few make funding agreements. Here though we have a great shot, soon I believe with funding. Then revenue comes with drug approval, so we are close.
Also, I believe the BLA submission will move the share price. We will see how much. And Mono pivotal approval. Then the partnership/licensing would be huge of course.
1
